Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) insider Linda Llewelyn sold 1,324 shares of the stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $8.16, for a total transaction of $10,803.84. Following the sale, the insider now directly owns 114,275 shares of the company's stock, valued at $932,484. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Linda Llewelyn also recently made the following trade(s):
- On Monday, September 16th, Linda Llewelyn sold 1,324 shares of Health Catalyst stock. The shares were sold at an average price of $8.43, for a total transaction of $11,161.32.
- On Thursday, August 15th, Linda Llewelyn sold 1,328 shares of Health Catalyst stock. The stock was sold at an average price of $6.57, for a total transaction of $8,724.96.
Health Catalyst Trading Down 0.8 %
HCAT opened at $8.65 on Friday. Health Catalyst, Inc. has a 1-year low of $5.42 and a 1-year high of $11.41. The company has a market cap of $510.65 million, a price-to-earnings ratio of -4.68 and a beta of 1.32. The company's fifty day moving average price is $7.67 and its two-hundred day moving average price is $6.93.
Single Stock Blueprint Available Now
From Opportunistic Trader | Ad
Market Wizard Larry Benedict is one of the most successful traders you'll ever meet...
But he doesn't make money the traditional way.
His approach has nothing to do with "buy and hold."
Larry reveals everything in this interview — including the name of the stock you need to get started
Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.08 by $0.04. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The company had revenue of $75.90 million during the quarter, compared to the consensus estimate of $74.96 million. During the same period in the previous year, the firm posted ($0.21) earnings per share. The firm's revenue for the quarter was up 3.7% on a year-over-year basis. As a group, equities analysts forecast that Health Catalyst, Inc. will post -0.35 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC grew its holdings in Health Catalyst by 461.0% during the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company's stock worth $41,000 after buying an additional 5,232 shares in the last quarter. Quarry LP grew its stake in shares of Health Catalyst by 59.4% in the 2nd quarter. Quarry LP now owns 7,002 shares of the company's stock worth $45,000 after acquiring an additional 2,610 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of Health Catalyst in the third quarter valued at about $59,000. Perfromance Wealth Partners LLC purchased a new stake in shares of Health Catalyst in the second quarter valued at about $64,000. Finally, Mackenzie Financial Corp bought a new position in shares of Health Catalyst during the second quarter valued at about $70,000. Institutional investors own 85.00% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the company. JPMorgan Chase & Co. increased their price target on Health Catalyst from $10.00 to $13.00 and gave the stock an "overweight" rating in a report on Wednesday, September 4th. Stephens decreased their target price on Health Catalyst from $8.00 to $7.00 and set an "equal weight" rating for the company in a research note on Thursday, August 8th. Piper Sandler lowered their target price on Health Catalyst from $14.00 to $11.00 and set an "overweight" rating for the company in a report on Monday, August 26th. Cantor Fitzgerald restated an "overweight" rating and set a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Finally, Evercore ISI lifted their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the company an "outperform" rating in a research note on Tuesday, October 8th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $11.58.
Get Our Latest Stock Report on Health Catalyst
About Health Catalyst
(
Get Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
